Wolverine Trading, LLC Prothena Corp Public LTD CO Call Options Transaction History

Wolverine Trading, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $29,079 - $47,088	-900 Reduced 11.11%	7,200 $261,000
Q3 2023 Nov 15, 2023	BUY	$47.3 - $70.6 $383,130 - $571,860	8,100 New	8,100 $390,000
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $334,628 - $806,379	13,300 New	13,300 $791,000
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $202,297 - $355,822	-8,900 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $193,706 - $336,996	-4,600 Reduced 34.07%	8,900 $425,000
Q1 2020 May 11, 2020	SELL	$7.54 - $15.77 $66,352 - $138,776	-8,800 Reduced 39.46%	13,500 $144,000
Q4 2019 Feb 12, 2020	SELL	$7.48 - $17.01 $15,708 - $35,721	-2,100 Reduced 8.61%	22,300 $352,000
Q3 2018 Nov 14, 2018	BUY	$12.7 - $15.79 $128,270 - $159,479	10,100 Added 70.63%	24,400 $319,000
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $399,685 - $644,072	14,300 New	14,300 $525,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $745M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.